Mankind Pharma share price: Going ahead, improving domestic volumes, rising chronic contribution and sustained export momentum are expected to support growth, say analysts.
The drugmaker's revenue rose 17.3 per cent to ₹4,338 crore in Q2 FY27, supported by strong demand for chronic therapies and growth in Bharat Serums and Vaccines' speciality portfolio.
Q2FY27 company results: Firms including Mankind Pharma, Dalmia Bharat, APL Apollo Tubes, and Aegis Logistics are also to release their July-September earnings today
The top 10 in August included Sun Pharma, Cipla, Abbott, Mankind Pharma, Torrent Pharmaceuticals, Alkem Laboratories, Intas Pharmaceuticals, Lupin, Zydus Lifesciences and Dr Reddy's Laboratories
Firm eyes more partnerships with Chinese pharmaceutical companies to expand its in-licensed drug pipeline as it seeks a larger presence in injectable diabetes therapies
Profit before tax rose 42.4 per cent to ₹769 crore as expenses grew slower than revenue and finance costs declined 35.6 per cent; tax expense more than doubled
Q4FY26 company results: Firms including Zydus Lifesciences, BASF India, PI Industries, Zee Entertainment, and Bosch Home Comfort India are also to release their January-March earnings today
The acquisition is expected to strengthen Mankind Pharma's presence in the central nervous system (CNS) segment and complement its existing neuro portfolio
JM Financial raised concerns around Mankind Pharma's recent BSV acquisition, which was executed at a high valuation and is expected to dilute return on capital
Mankind Pharma recorded profit after tax (PAT) of ₹414 crore, up from ₹378 crore in the same quarter last year. Its revenue from operations also grew 11.5 per cent
Mankind Pharma posted a 9.5 per cent rise in Q3FY26 net profit and 11.5 per cent growth in revenue, driven by strong domestic demand for chronic therapies
Mankind Pharma has entered a licensing agreement with Actimed Therapeutics to develop and commercialise cachexia treatment products across India and neighbouring South Asian markets
Mankind Pharma's Q2 FY26 profit fell to Rs 520 crore on higher finance and input costs, even as strong domestic and export growth lifted revenue by over 20%.
Chairman and Managing Director of KEI Industries Anil Gupta assumed charge as the Senior V-P, while Sanjay Singhania, managing director and CEO of Epack Prefab Technologies, has been named V-P
Mankind Pharma has received CDSCO approval to initiate Phase 1 trials of MKP11093, a novel JAK-1 inhibitor for autoimmune disorders, as part of its expanding R&D pipeline
